Clinical trials: Multiple Sclerosis, Acute Relapsing
Multiple Sclerosis, Functional Neurological Disorders
Bridging Gaps in the Multidimensional Assessment and Management of Overlapping Symptoms in Multiple Sclerosis and Functional Motor Disorders: Prevalence and Rehabilitation Effectiveness
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that may cause a broad range of motor and non-motor symptoms.
- Trial name
- NCT07856485
- Testing
- Functional Motor Disorder-Specific Multidisciplinary Rehabilitation, Conventional Multiple Sclerosis Rehabilitation
- Where
- 2 sites in Italy
- Volunteers
- 192 people
- Sponsor
- IRCCS San Raffaele
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Multiple Sclerosis, Acute Relapsing
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS).
- Trial name
- NCT02398461
- Testing
- rHIgM22
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis, Relapsing-Remitting
Acute Intermittent Hypoxia in Persons With Multiple Sclerosis
The overall objective of this project is to investigate the effectiveness of Acute Intermittent Hypoxia (AIH), to improve muscle strength and activity level in individuals with relapsing-remitting MS.
- Trial name
- NCT04280484
- Testing
- Intermittent Hypoxia
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis
Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks
This clinical trial compares the relative efficacy of treating acute exacerbations of relapsing forms of Multiple Sclerosis with equivalent doses of oral and intravenous (IV) methylprednisolone.
- Trial name
- NCT00418145
- Testing
- megadose oral methylprednisolone, IV methylprednisolone
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fred Lublin
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol.
- Trial name
- NCT01039103
- Testing
- PEG-liposomal prednisolone sodium phosphate, Methylprednisolone
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Lakefront Biotherapeutics NV
Multiple Sclerosis
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
We are studying this investigational drug treatment, comparing it with placebo, to evaluate whether it is effective in reducing the number of MRI lesions with a minimum number of side effects.
- Trial name
- NCT00079495
- Testing
- NBI-5788
- Volunteers
- 150 people
- Sponsor
- Neurocrine Biosciences
Multiple Sclerosis
The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients:
This work is aimed to assess the short term effect of pulse therapy on clinical and neurophysiological course before and after pulse therapy in order to understand the possible mechanism of action of steroid therapy on RRMS…
- Trial name
- NCT06280131
- Volunteers
- 30 people
- Sponsor
- Assiut University
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
The Synergistic Effects of AIH and FES in Persons With MS
The purpose of this study is to examine how neuromuscular electrical stimulation (NMES), may synergistically enhance corticospinal excitability in people with relapsing form multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06413602
- Testing
- Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06390930
- Testing
- Acute Intermittent Hypoxia
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis
Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis
The management of MS-patients requires treatment with immune-modifying or immune-suppressive agents to prevent new relapses and progression of disability.
- Trial name
- NCT01411514
- Testing
- Prednisone
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- Claudio Gobbi
Multiple Sclerosis, Multiple Sclerosis, Acute Relapsing
Plasma Exchanges in Multiple Sclerosis (MS) Relapses
In more than 40 % of multiple sclerosis (MS) patients experiencing relapse, residual disability accumulates in spite of steroid treatment.
- Trial name
- PLASMASEP (NCT01442233)
- Testing
- plasma exchange
- Where
- 6 sites in France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis
Effects of Acthar on Recovery From Cognitive Relapses in MS
The purpose of this study is to evaluate the effect of a medication called Acthar on recovery from multiple sclerosis-related relapses that impact cognition.
- Trial name
- NCT02290444
- Testing
- Adrenocorticotropic Hormone
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis, Acute Relapsing, Multiple Sclerosis
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Multiple Sclerosis is a chronic autoimmune disease associated with inflammatory response harmful for the Central Nervous System.
- Trial name
- 5-HTSEP (NCT04546698)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
Positron-Emission Tomography, Multiple Sclerosis
Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8101 for investigation in patients with Multiple Sclerosis compared to healthy volunteers
- Trial name
- NCT01031199
- Testing
- F-18 FEDAA1106 (BAY85-8101)
- Where
- 2 sites in Australia, Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis Relapsing Remitting, Treatment
Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration
This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis
- Trial name
- IN-DXM-EMRR (NCT06223074)
- Testing
- IV Methylprednisolone administration, Nasal Methylprednisolone (MT)
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Universidad Nacional Autonoma de Mexico
Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
- Trial name
- SONICS (NCT03942952)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
The purpose of this study is to compare intramuscular (IM) ACTH (adrenocorticotropin hormone) and intravenous (IV) methylprednisolone (Solumedrol) for the treatment of an MS (Multiple Sclerosis) relapse (exacerbation) after…
- Trial name
- RECLAIM (NCT00947895)
- Testing
- Methylprednisolone, ACTH
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neurologique Foundation, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate…
- Trial name
- ORION (NCT05605782)
- Where
- United States
- Volunteers
- 9,000 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis, RRMS
Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?
The MYTH-MS study is a multicenter prospective study investigating the occurrence of clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) in the absence of radiological activity on MRI.
- Conditions
- Multiple Sclerosis, RRMS, Multiple Sclerosis (MS) - Relapsing-remitting
- Trial name
- MYTH-MS (NCT07545889)
- Testing
- Early Cerebro-spinal MRI, Biomarker Assessment, Clinical and Neuropsychological Evaluations
- Where
- 8 sites in France
- Volunteers
- 136 people
- Sponsor
- University Hospital, Strasbourg, France